Pharmacokinetics of a Novel Piperaquine Dispersible Granules Formulation Under Fasting and Various Fed Conditions Versus Piperaquine Tablets When Fasted in Healthy Tanzanian Adults: A Randomized, Phase I Study
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70133 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Florence A Milando und 31 weiteren Autor:innen. Beteiligte Einrichtung: Ifakara Health Institute (IHI), Bagamoyo, Tanzania. Hauptthemen laut MEDLINE: Antimalarials, Fasting, Food-Drug Interactions, Quinolines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Piperaquine tetraphosphate (PQP), a long‐acting antimalarial, is being considered in a combination for chemoprevention. Dihydroartemisinin‐piperaquine tablets (hard and dispersible) approved for the treatment of acute uncomplicated malaria should be administered in a fasted state, as PQP bioavailability increases with food. A new taste‐masked dispersible granules PQP formulation aims to minimize the impact of food on drug exposure. This randomized, open label, parallel group, Phase I pilot study was conducted between 24th July 2023, and 3rd January 2024, at the Ifakara Health Institute, Bagamoyo, Tanzania in 60 healthy African adults (five cohorts of 12). Single‐dose pharmacokinetics and relative systemic exposure of the oral PQP dispersible granules formulation prototype (320 mg) was compared to the hard tablet when fasted and PQP granules in three different fed conditions. In the fasted state, the relative exposure of PQP granules versus the tablet was 73.9% (90% CI 48.3, 113.0) for C max and 86.5% (68.2, 109.6) for AUC 0‐t . Following a typical East African low‐fat meal, a standard high‐fat meal, or 250 mL whole milk, the relative exposure of PQP granules versus the fasted state was 202% (90% CI 132, 311), 275% (193, 391), and 294% (203, 425) for C max and 164% (124, 217), 184% (148, 228), and 195% (147, 259) for AUC 0‐t , respectively. Both formulations were well tolerated with one drug‐related adverse event (moderate migraine). No severe or serious adverse events or clinically relevant laboratory or electrocardiograph changes were observed. PQP dispersible granules had lower systemic exposures versus the tablet when fasted, whereas various meals increased drug exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ifakara Health Institute (IHI), Bagamoyo, Tanzania.
- Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
- University of Basel, Basel, Switzerland.
- MMV Medicines for Malaria Venture, Geneva, Switzerland.
- Mangareva SRL, Kraainem, Belgium.
ORCID-Profile: Florence A Milando, Said Jongo, Salim Abdulla, Gloria Nyaulingo, Anneth-Mwasi Tumbo, Juliether Tiago, Beatus S Bongole, Ashura Mirambo, Kamaka Kassimu, Hussein Mbarak, Mohammed A Rashid, Ali Hamad, Michael Mihayo, Tunu Ndanzi, Omary Zuberi, Naima Saadia, Mariam Somboka, Mariam Yamba-Yamba, Theresia Ngonyani, Amina Nditi, Margaret Msuya, Bakari Mwalimu, Hajirani M Msuya, Khamis Awadh, Ali Ali, Anne Claire Marrast, Denis Gossen, Alice Neequaye, Myriam El-Gaaloul, Hanu Ramachandruni, Isabelle Borghini-Fuhrer
Zitieren
APA
Milando, F. A., Jongo, S., Abdulla, S., Nyaulingo, G., Tumbo, A. M., Mswata, S., Tiago, J., Bongole, B. S., Mirambo, A., Kassimu, K., Mbarak, H., Rashid, M. A., Hamad, A., Mihayo, M., Ndanzi, T., Zuberi, O., Saadia, N., Somboka, M., Yamba-Yamba, M., …, & Borghini-Fuhrer, I. (2025). Pharmacokinetics of a Novel Piperaquine Dispersible Granules Formulation Under Fasting and Various Fed Conditions Versus Piperaquine Tablets When Fasted in Healthy Tanzanian Adults: A Randomized, Phase I Study. Clinical and Translational Science. https://doi.org/10.1111/cts.70133
Vancouver
Milando FA, Jongo S, Abdulla S, Nyaulingo G, Tumbo AM, Mswata S, et al. Pharmacokinetics of a Novel Piperaquine Dispersible Granules Formulation Under Fasting and Various Fed Conditions Versus Piperaquine Tablets When Fasted in Healthy Tanzanian Adults: A Randomized, Phase I Study. Clinical and Translational Science. 2025. doi:10.1111/cts.70133
BibTeX
@article{Milando2025,
author = {Milando, Florence A and Jongo, Said and Abdulla, Salim and Nyaulingo, Gloria and Tumbo, Anneth-Mwasi and Mswata, Sarah and Tiago, Juliether and Bongole, Beatus S and Mirambo, Ashura and Kassimu, Kamaka and Mbarak, Hussein and Rashid, Mohammed A and Hamad, Ali and Mihayo, Michael and Ndanzi, Tunu and Zuberi, Omary and Saadia, Naima and Somboka, Mariam and Yamba-Yamba, Mariam and Ngonyani, Theresia and Nditi, Amina and Msuya, Margaret and Mwalimu, Bakari and Msuya, Hajirani M and Awadh, Khamis and Ali, Ali and Marrast, Anne Claire and Gossen, Denis and Neequaye, Alice and El-Gaaloul, Myriam and Ramachandruni, Hanu and Borghini-Fuhrer, Isabelle},
title = {Pharmacokinetics of a Novel Piperaquine Dispersible Granules Formulation Under Fasting and Various Fed Conditions Versus Piperaquine Tablets When Fasted in Healthy Tanzanian Adults: A Randomized, Phase I Study},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70133}
}
EUVIMED